UniQure Up 6% On FDA Approval Of Gene Therapy Drug

Shares of gene therapy company uniQure N.V. (QURE) are rising 6 percent on Wednesday's trading continuing their upward movement since the past few days.

The stock has been positively impacted by news of uniQure's partner, global biotechnology leader CSL receiving approval from the U.S Food and Drug Administration for HEMGENIX (etranacogene dezaparvovec-drlb), which is a one-time gene therapy for the treatment of adults 18 years of age and older living with hemophilia B.

Currently at $24.30, the stock has traded between $12.52 and $30.41 during the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.
Follow RTT